These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28082068)

  • 1. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
    Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
    Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4.
    Ren Q; Liu X; Yan G; Nie B; Zou Z; Li J; Chen Y; Wei Y; Huang J; Luo Z; Gu B; Goldmann S; Zhang J; Zhang Y
    J Med Chem; 2018 Feb; 61(3):1355-1374. PubMed ID: 29381358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
    Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS
    Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
    Ma Y; Zhao S; Ren Y; Cherukupalli S; Li Q; Woodson ME; Bradley DP; Tavis JE; Liu X; Zhan P
    Eur J Med Chem; 2021 Dec; 225():113780. PubMed ID: 34438123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    Wang J; Zhang H; Zhang Y; Jiang D; Li J; Goldmann S; Ren Q; Fei R; Wang X; Wei L
    J Med Virol; 2017 Oct; 89(10):1804-1810. PubMed ID: 28401569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new series of HAPs as anti-HBV agents targeting at capsid assembly.
    Yang XY; Xu XQ; Guan H; Wang LL; Wu Q; Zhao GM; Li S
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4247-9. PubMed ID: 25127104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
    Qiu Z; Lin X; Zhou M; Liu Y; Zhu W; Chen W; Zhang W; Guo L; Liu H; Wu G; Huang M; Jiang M; Xu Z; Zhou Z; Qin N; Ren S; Qiu H; Zhong S; Zhang Y; Zhang Y; Wu X; Shi L; Shen F; Mao Y; Zhou X; Yang W; Wu JZ; Yang G; Mayweg AV; Shen HC; Tang G
    J Med Chem; 2016 Aug; 59(16):7651-66. PubMed ID: 27458651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation.
    Lu D; Liu F; Xing W; Tong X; Wang L; Wang Y; Zeng L; Feng C; Yang L; Zuo J; Hu Y
    ACS Infect Dis; 2017 Mar; 3(3):199-205. PubMed ID: 27989113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers.
    Zhao N; Jia B; Zhao H; Xu J; Sheng X; Luo L; Huang Z; Wang X; Ren Q; Zhang Y; Zhao X; Cui Y
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.
    Boucle S; Lu X; Bassit L; Ozturk T; Russell OO; Amblard F; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2017 Feb; 27(4):904-910. PubMed ID: 28094179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
    Qiu Z; Lin X; Zhang W; Zhou M; Guo L; Kocer B; Wu G; Zhang Z; Liu H; Shi H; Kou B; Hu T; Hu Y; Huang M; Yan SF; Xu Z; Zhou Z; Qin N; Wang YF; Ren S; Qiu H; Zhang Y; Zhang Y; Wu X; Sun K; Zhong S; Xie J; Ottaviani G; Zhou Y; Zhu L; Tian X; Shi L; Shen F; Mao Y; Zhou X; Gao L; Young JAT; Wu JZ; Yang G; Mayweg AV; Shen HC; Tang G; Zhu W
    J Med Chem; 2017 Apr; 60(8):3352-3371. PubMed ID: 28339215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells.
    Huber AD; Wolf JJ; Liu D; Gres AT; Tang J; Boschert KN; Puray-Chavez MN; Pineda DL; Laughlin TG; Coonrod EM; Yang Q; Ji J; Kirby KA; Wang Z; Sarafianos SG
    mSphere; 2018 Apr; 3(2):. PubMed ID: 29669885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors.
    Jia H; Yu J; Du X; Cherukupalli S; Zhan P; Liu X
    Eur J Med Chem; 2020 Sep; 202():112495. PubMed ID: 32712535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.
    Wu G; Liu B; Zhang Y; Li J; Arzumanyan A; Clayton MM; Schinazi RF; Wang Z; Goldmann S; Ren Q; Zhang F; Feitelson MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5344-54. PubMed ID: 23959305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors.
    Pan T; Ding Y; Wu L; Liang L; He X; Li Q; Bai C; Zhang H
    Eur J Med Chem; 2019 Mar; 166():480-501. PubMed ID: 30739828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection.
    Ko C; Bester R; Zhou X; Xu Z; Blossey C; Sacherl J; Vondran FWR; Gao L; Protzer U
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.
    Wu S; Zhao Q; Zhang P; Kulp J; Hu L; Hwang N; Zhang J; Block TM; Xu X; Du Y; Chang J; Guo JT
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1.
    Bourne CR; Finn MG; Zlotnick A
    J Virol; 2006 Nov; 80(22):11055-61. PubMed ID: 16943288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays.
    Wang Y; Wang Z; Liu J; Wang Y; Wu R; Sheng R; Hou T
    Bioorg Med Chem; 2021 Apr; 36():116096. PubMed ID: 33721800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.